Our Leadership Over Time
We continue to develop cereblon E3 ligase modulators and
ligand-directed degraders that may be able to address previously
“undruggable” proteins that play a role in disease pathology.
We are working on agents with a mechanism of action similar
to cereblon E3 ligase modulators, but which co-opt E3 ligase
complex members other than cereblon.
Our ongoing investments further our commitment and
leadership in providing solutions that may selectively degrade
previously “undruggable” protein targets with clinical relevance.
Krönke J et al. Science. 2014;343(6168):301-305.
Lu G et al. Science. 2014;343(6168):305-309.
Gandhi AK et al. Br J Haematol. 2014;164(6):811-821.
Ito T, Handa H. Int J Hematol. 2016;104(3):293-299.
Matyskiela ME et al. Nature. 2016;535(7611):252-257.
BMS. Data on file.
Nowakowski GS. Blood. 2015;126(6):698-700.
Ito T et al. Science. 2010;327(5971):1345-1350.
Chamberlain PP et al. Nat Struct Mol Biol. 2014;21(9):803-809.
Hagner PR et al. Blood. 2015;126(6):779-789.
Chamberlain PP, Hamann LG. Nat Chem Biol. 2019;15(10):937-944.
Hershko A. J Biol Chem. 1988;263(30):15237-15240.
Hershko A et al. J Biol Chem. 1983;258(13):8206-8214.
Hershko A et al. Proc Natl Acad U S A. 1984;81:1619-1623.
Hough R et al. J Biol Chem. 1986;261(5):2400-2408.
Hough R et al. J Biol Chem. 1987;262(17):8303-8313.
Holstein SA et al. Ther Adv Hematol. 2018;9(7);175-190.
U.S. Food and Drug Administration. Lenalidomide (Revlimid).
https://www.fda.gov/drugs/resources-information-approved-drugs/lenalidomide-revlimid. Accessed January 22, 2021.
Anderson KC et al. J Natl Compr Canc Netw. 2009;7(9):908-942.
U.S. Food and Drug Administration. Pomalyst.
https://www.accessdata.fda.gov/scripts/cder/daf/
index.cfm?
event=overview.process&ApplNo=204026. Accessed January 22, 2021.
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
NCT02185040. https://clinicaltrials.gov/ct2/show/NCT02185040.
Accessed January 22, 2021.
A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma. NCT02773030.
https://clinicaltrials.gov/ct2/show/NCT02773030.
Accessed January 22, 2021.
A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PLATFORM). NCT03310619. https://clinicaltrials.gov/ct2/show/NCT03310619.
Accessed January 22, 2021.
A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas. NCT04464798. https://clinicaltrials.gov/ct2/show/NCT04464798. Accessed January 22, 2021.
Surka C et al. Blood. 2021;137(5):661-677.
Iberdomide (CC-220) Maintenance After ASCT in Newly Diagnosed MM Patients. NCT04564703. https://clinicaltrials.gov/ct2/show/NCT04564703. Accessed January 22, 2021.
Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone (ICON). NCT04392037. https://clinicaltrials.gov/ct2/show/NCT04392037.
Accessed January 22, 2021.
A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM). NCT03374085. https://clinicaltrials.gov/ct2/show/NCT03374085.
Accessed April 7, 2021.
A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM). NCT03989414. https://clinicaltrials.gov/ct2/show/NCT03989414.
Accessed April 7, 2021.
Lopez-Girona A et al. Blood. 2019;134(S1):1812.
A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. NCT04434196.
https://clinicaltrials.gov/ct2/
show/NCT04434196. Accessed April 8, 2021
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Rituximab in Subjects With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL). NCT03930953. https://clinicaltrials.gov/ct2/show/NCT03930953.
Accessed April 8, 2021.
BMS Investor Series. Early Pipeline & Immuno-oncology. June 22, 2020.
https://s21.q4cdn.com/104148044/files/
doc_presentations/2020/BMY-Investor
-Series-Day1.pdf. Accessed April 7, 2021.
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-94676 in Subjects With Metastatic Castration-Resistant Prostate Cancer. NCT04428788. https://clinicaltrials.gov/ct2/
show/NCT04428788.
Accessed April 7, 2021.